Changing the paradigm of treating neurodegenerative disease
Our mission is to translate unique genetic and biochemical insights regarding lipid biology into therapies that promote brain health and repair. We believe our novel technology platform and approach will unlock new opportunities to address significant unmet need across a range of acute and chronic conditions, including Traumatic Brain Injury, Stroke, Multiple Sclerosis, and Alzheimer’s Disease.
Great teams are required to achieve great success
We are a growing team of scientists and entrepreneurs dedicated to advancing our technology in service of patients and their loved ones. With a diverse culture of experience and perspective, we strive to support and challenge one another, fostering an environment of care, respect, and collaboration. New ideas and innovation fuel us. Science and data guide us. Novel challenges and opportunities bring out our best. Passionate and driven, we aspire to overcome obstacles with creativity and careful risk-taking, knowing that we are making a difference in the lives of patients.
At Kisbee, we believe that great teams are built on a foundation of kindness, honesty, and balance. We work hard, but recognize that we all have lives outside the lab and office. We celebrate our successes as much as our failures, knowing that both are stepping stones on the journey to changing the way we approach brain health. Together, we will redefine the way we treat neurodegenerative disease.
Meet the experts behind our vision
Kisbee is an exciting fast-growing company with tremendous career growth opportunity. We are actively hiring across a range of roles in R&D, HR, Finance, and Operations. To inquire about open roles, please email recruiting@kisbeetx.com
Benjamin F. Cravatt, Ph.D., is a the Gilula Chair of Chemical Biology and Professor in the Department of Chemistry at The Scripps Research Institute. His research group develops and applies chemical proteomic technologies for protein and drug discovery on a global scale and has particular interest in studying biochemical pathways in the nervous system and cancer. Dr. Cravatt is a co-founder of Activx Biosciences (acquired by Kyorin Pharmaceuticals), Abide Therapeutics (acquired by Lundbeck Pharmaceuticals), and Vividion Therapeutics. His honors include a Searle Scholar Award, the Eli Lilly Award in Biological Chemistry, a Cope Scholar Award, the ASBMB Merck Award, the Royal Society of Chemistry Jeremy Knowles Award, and memberships in the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts and Sciences.
Dr. Cravatt obtained his undergraduate education at Stanford University, receiving a B.S. in the Biological Sciences and a B.A. in History. He then received a Ph.D. from The Scripps Research Institute (TSRI) in 1996, and joined the faculty at TSRI in 1997.
